Insulin Resistance Drug Protects Neurons from NO Damage: Potential CFS Implications~!

Backgrond: A recent study has shown improvements in CFS mouse model after the use of pioglitazone and caffeic acid. Other studies suggest pathogenic influences on CFS including exposure to gram (-) bacteria. Rosiglitazone, another PPAR-gamma agonist, has shown positive effects as an anti-inflammatory in conditions that lead to neurodegenerative disease like Parkinson's. Schintu demontrates that Rosiglitazone inhibits microglia reactivity.

"pioglitazone protects dopaminergic neurons against LPS insult at least via inhibiting iNOS expression and NO generation, which is potentially mediated via inhibition of p38 MAPK activity. In addition, the PI3K pathway actively participates in the negative regulation of LPS-induced NO production"

Read more:CiteULike: Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt.:


For further Reading: HEIRS Research Blog July 24, 2010
***Inflammation, Insulin Resistance and Decreased PPARs-- A Pathway to CFS?


Additional Resource:
*Schintu, N., Frau, L., Ibba, M., Caboni, P., Garau, A., Carboni, E., and Carta, A. R. (2009). Ppar-gamma-mediated neuroprotection in a chronic mouse model of parkinson's disease. The European journal of neuroscience, 29(5):954-963.
http://www.citeulike.org/user/HEIRS/article/4136907?show_msg=already_posted